EXPANSORB®

Catalog

CONTINUUM OF PROGRESS

• Active DMFs i.e. US type IV (Excipients) • Dedicated onsite R&D capabilities to any fine tuning from lab to industrial scale • Regulatory services support : IMPD, DMF Filing • Produced in Europe (Aramon, France)• GMP compliant (EU, USFDA)• Classic and ultrapure low-monomer and powder grades available .

SEQENS UNIQUE OFFER

20+ years expertise on PLGA manufacturing within several on-the-market formulations

Contact us for any custom or fine-tuning needs

Lactide enantiomer ratio (D,L)

Catalysts

Residual monomer content

Copolymers with Poly(ε-caprolactone), PEG...Acid, ester, PEG, Saccharide chain termination...

IV/Mw

Residual catalyst amount

3

0

10

20

30

40

50

60

70

80

90

100

110

0 5 10 15 20 25 30 35

API R

ELEA

SE [

%]

TIME [DAYS]

EXPANSORB® DLG 50-2AEXPANSORB® DLG 50-5AEXPANSORB® DLG 75-5A

Chain length

Take the control of your drug release !

* (0.5% CHCl3, 25°C)  ** (Indicative, PS STD)Bacterial Endotoxins (<5IU/g); TAMC ( ≤100 CFU/g); TYMC (≤50 CFU/g)

LA GA END GROUP EXPANSORB CLASS REFERENCE INHERENT VISCOSITY* Mw (kDa) **

100 COOH EXPANSORB® DL 100-1A 10P006 0.05-0.20 04-20100 COOH EXPANSORB® DL 100-2A 10P005 0.15-0.30 10-25100 COOH EXPANSORB® DL 100-5A 10P018 0.40-0.60 40-75100 COOH EXPANSORB® DL 100-7A 10P036 0.60-0.80 65-110100 ESTER EXPANSORB® DL 100-2E 10P014 0.15-0.30 10-25100 PEG EXPANSORB® DL 100-4P 10P045 0,33-0,58100 PEG EXPANSORB® DL 100-7P 10P047 0,59-0,8495 5 COOH EXPANSORB® DLG 95-2A 10P023 0.15-0.25 05-2095 5 COOH EXPANSORB® DLG 95-4A 10P025 0.25-0.50 25-6090 10 COOH EXPANSORB® DLG 90-5A 10P007 0.35-0.55 30-7090 10 COOH EXPANSORB® DLG 90-7A 10P029 0.60-0.70 60-9585 15 COOH EXPANSORB® DLG 85-12A 10P040 1.00-1.3085 15 COOH EXPANSORB® DLG 85-2A 10P020 0.15-0.25 10-2085 15 COOH EXPANSORB® DLG 85-3A 10P038 0.25-0.35 14-2685 15 COOH EXPANSORB® DLG 85-7A 10P008 0.55-0.75 65-9585 15 ESTER EXPANSORB® DLG 85-12E 10P043 1.00-1.30 150-22085 15 ESTER EXPANSORB® DLG 85-3E 10P044 0.25-0.35 14-2685 15 ESTER EXPANSORB® DLG 85-7E 10P009 0.55-0.75 65-9575 25 COOH EXPANSORB® DLG 75-10A 10P004 0.80-1.10 100-166 75 25 COOH EXPANSORB® DLG 75-2A 10P015 0.08-0.21 05-2075 25 COOH EXPANSORB® DLG 75-4A 10P042 0.38-0.48 40-5575 25 COOH EXPANSORB® DLG 75-5A 10P002 0.38-0.64 39-8075 25 COOH EXPANSORB® DLG 75-7A 10P021 0.60-0.70 65-85

75 25 COOH EXPANSORB® DLG 75-8A 10P003 0.60-0.90 70-13075 25 ESTER EXPANSORB® DLG 75-2E 10P033 0.15-0.30 10-2575 25 ESTER EXPANSORB® DLG 75-4E 10P035 0.30-0.50 25-6075 25 ESTER EXPANSORB® DLG 75-7E 10P011 0.66-0.80 80-11575 25 ESTER EXPANSORB® DLG 75-9E 10P027 0.75-1.00 100-15075 25 PEG EXPANSORB® DLG 50-6P 10P046 0.50-0.70 45-8075 25 PEG EXPANSORB® DLG 50-8P 10P048 0.70-0.90 80-12565 35 COOH EXPANSORB® DLG 65-3A 10P030 0.25-0.35 15-4065 35 COOH EXPANSORB® DLG 65-6A 10P013 0.50-0.65 45-8565 35 ESTER EXPANSORB® DLG 65-6E 10P010 0.50-0.65 45-8555 45 COOH EXPANSORB® DLG 55-5A 10P031 0.40-0.50 42-65

50 50 COOH EXPANSORB® DLG 50-2A 10P019 0.15-0.25 05-2050 50 COOH EXPANSORB® DLG 50-3A 10P017 0.25-0.40 15-4050 50 COOH EXPANSORB® DLG 50-5A 10P001 0.40-0.50 42-6550 50 COOH EXPANSORB® DLG 50-6A 10P034 0.55-0.65 60-8550 50 COOH EXPANSORB® DLG 50-8A 10P012 0.65-0.90 80-13050 50 ESTER EXPANSORB® DLG 50-2E 10P024 0.15-0.25 05-2050 50 ESTER EXPANSORB® DLG 50-6E 10P022 0.50-0.65 60-8550 50 ESTER EXPANSORB® DLG 50-7E 10P016 0.60-0.70 70-10050 50 PEG EXPANSORB® DLG 50-6P 10P037 0,55-0,70 36-7750 50 PEG EXPANSORB® DLG 50-7P 10P026 0,71-0,86 77-118

45 55 COOH EXPANSORB® DLG 45-2A 10P032 n/a 15-30

D,L10L-

-Lactide : Lactide: 90 COOH EXPANSORB® DLL 10-15A 10P039 1.30-1.70

Ultrapure LMP (Low Monomer and Powder) Grade available !With <0,5% monomer content

NEW !

Seqens is an integrated global leader in pharmaceutical solutions and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and custom-made solutions to its customers. In the pharmaceutical industry, Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. Seqens also offers a large portfolio of APIs and proprietary products.

DISCOVER SEQENS PHARMA SOLUTIONS PRODUCTS & SERVICES OFFER

About Seqens

3200 people

300 scientists, experts and engineers

7 R&D centers

1000 clients in more

than 80 countries

24 manufacturing sites

Contact : DDMM@SEQENS.COM

WWW.SEQENS.COM

21 CHEMIN DE LA SAUVEGARDE«21 ECULLY PARC»CS 3316769134 ECULLY CEDEXTEL. +33 04 26 99 18 00FAX. +33 04 26 99 18 38

Drug Delivery & Medical Material

Custom manufactuting

Early stagemanufacturing

API Biocatalysis services

21 CHEMIN DE LA SAUVEGARDECS 3316769130 ECULLY CEDEXTEL. +33 (0) 4 26 99 18 00FAX. +33 (0) 4 26 99 18 38

#Pha

rma

Solu

tion

#Spe

cial

ty

ingr

edie

nts

LAHR ARAMON

BOSTON

MONTREAL

MIDDLESBROUGH

Biocatalysis Small molecules & polymers

Early phase projects

Accelerated R&D

Drug delivery polymers

Electronics

Cosmetics & fine chem